|Mr. Mark J. Enyedy||Pres, CEO, Interim Principal Financial Officer & Director||1.26M||N/A||1964|
|Mr. Craig Barrows||Exec. VP, Gen. Counsel & Sec.||578.88k||N/A||1955|
|Ms. Courtney O'Konek||Sr. Director of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Ms. Audrey Bergan||VP & Chief HR Officer||N/A||N/A||N/A|
|Dr. Theresa G. Wingrove||Sr. VP of Regulatory Affairs & Quality||N/A||N/A||1958|
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. ImmunoGen, Inc. has collaborations with Roche, Amgen/Oxford BioTherapeutics, sanofi-aventis U. S. LLC, Biotest AG, Bayer HealthCare AG, Novartis Institutes for BioMedical Research, Inc., CytomX Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Fusion Pharmaceuticals Inc., Debiopharm International SA, Jazz Pharmaceuticals Ireland Limited, and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
ImmunoGen, Inc.’s ISS Governance QualityScore as of February 3, 2020 is 9. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 5; Compensation: 10.